The awards provide $500,000 per year for up to five years to the winners to support their research projects. The awards are “intended to stimulate high-impact research that may lead to groundbreaking opportunities for the prevention and treatment of HIV/AIDS in drug users,” according to the NIDA. This is the 11th year of the Avant-Garde Awards.
Dr. Landau, a professor in the microbiology department at New York City-based NYU Langone Health, will use the funds for his project titled, “Therapeutic Dendritic Cell Vaccine for HIV.”
The project aims to develop a therapeutic vaccine that improves immune response to HIV, thereby allowing patients to discontinue or reduce antiretroviral drug regimens.
The other two 2018 Avant-Garde Award winners are Catherine A. Blish, PhD, MD, of Stanford University in Palo Alto, Calif., and Sara L. Sawyer, PhD, of University of Colorado Boulder.
More articles on healthcare quality:
Viewpoint: How physicians can compassionately pronounce patient’s death
Wisconsin nurse under investigation for injuries to babies allegedly fired by UW hospital
WSJ report spurs House oversight of hospital accreditation processes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.